Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532 61. S4.1-5. Group HPSC. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular out- comes in 20536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45:645 54.; discussion 53 4. S4.1-6. Randomised trial of cholesterol lowering in 4444 patients with coro- nary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383 9. S4.1-7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investiga- tors. N Engl J Med. 1996;335:1001 9. S4.1-8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349 57. S4.1-9. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153 62. S4.1-10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23 33. S4.1-11. Knopp RH, d Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in sub- jects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabe- tes mellitus (ASPEN). Diabetes Care. 2006;29:1478 85. S4.1-12. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid- lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44:1772 9. S4.1-13. Serruys PW, de Feyter P, Macaya C, et al. 